NCT01733407View on ClinicalTrials.gov

L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

July 31, 2017

Conditions

Hereditary Sensory and Autonomic Neuropathy Type I

Interventions

DRUG

L-serine

400mg/kg/d L-serine or placebo divided TID for year 1, then crossover of placebo arm so that all patients on 400mg/kg/d L-serine divided TID for year 2.

DRUG

placebo

400mg/kg/d divided TID for year 1 only.

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

01605

UMass Medical Center, Worcester

All Listed Sponsors

lead

Massachusetts General Hospital

OTHER

NCT01733407 - L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1 | Biotech Hunter | Biotech Hunter